平行支架与烟囱腔内技术(PEACE)注册研究:急诊修复复杂腹主动脉瘤的结局
该多中心回顾性研究纳入118例因复杂腹主动脉瘤行急诊烟囱腔内修复(chEVAR)的患者,平均年龄77岁,66.1%为破裂。技术成功率90.6%,30天死亡率17.7%;远期再干预率16.1%,5年和7年动脉瘤相关死亡率免除率分别为58%和53%。chEVAR急诊用于复杂形态腹主动脉瘤技术成功率高、早期结局可接受,但远期再干预和死亡风险较高。
要点
- 急诊chEVAR技术成功率90.6%,30天死亡率17.7%。
- 5年和7年动脉瘤相关死亡率免除率分别为58%和53%。
- 远期再干预率16.1%,主要因Ia型和Ib型内漏。
核心结论
- 急诊chEVAR用于复杂形态腹主动脉瘤技术成功率高、早期结局可接受,但远期再干预和死亡率较高。
- 当标准开放手术和腔内技术不可行时,chEVAR可作为急诊复杂主动脉瘤的合理替代技术。
研究设计与样本
- 多中心回顾性研究,纳入截至2021年6月所有连续接受急诊chEVAR(至少一个烟囱/平行支架)的患者,共118例。
- 患者平均年龄77(8)岁,72.0%为男性,78例(66.1%)因主动脉破裂。
- 平均每例使用烟囱支架1.6(0.7)个,平均随访4(3)年。
主要发现
- 技术成功率为90.6%,30天死亡率为17.7%。
- 估计总生存率3年为69±5%,5年为45±6%,7年为32±6%。
- 动脉瘤相关死亡率免除率5年为58±6%,7年为53±6%;围术期30天存活者中5年为73±6%,7年为66±7%。
- 5年和7年主要靶血管通畅率均为87±4%,肾动脉最常受累。
- 晚期再干预率为16.1%,25次再干预中Ia型内漏占8次(32%),Ib型内漏占5次(20%)。
临床怎么用
- 对于急诊复杂形态腹主动脉瘤且标准开放和腔内技术不可行的患者,可考虑chEVAR作为替代方案。
- 术后需长期随访监测内漏和靶血管通畅情况,因远期再干预率较高。
局限性
- 本研究为多中心回顾性研究,未设对照组。
- 样本量有限(118例),随访时间平均4年。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chimney endovascular aneurysm repair (chEVAR) techniques have been described to manage a group of patients who are unsuitable for either open aortic aneurysm surgery or a variety of standard endovascular repair techniques. The aim of this study was to assess the long-term clinical outcomes of chEVAR in emergency settings for patients with abdominal aortic aneurysms that have complex morphology. METHODS: This was a multicentre retrospective study that included all consecutive patients undergoing urgent chEVAR with at least one chimney/parallel graft up to June 2021. Outcomes that were captured included 30-day mortality, long-term overall survival, aneurysm-related mortality, chimney-related complications, and target vessel patency. RESULTS: Some 118 patients (mean(s.d.) age of 77(8) years; 72.0% male) underwent urgent or emergency chEVAR, 78 (66.1%) due to aortic rupture. The mean(s.d.) number of chimneys used per patient was 1.6(0.7). Technical success was achieved in 90.6% of patients, with a 30-day mortality rate of 17.7%. The mean follow-up was 4(3) years. Estimated overall survival was 69 ± 5% at 3 years, 45 ± 6% at 5 years, and 32 ± 6% at 7 years. Freedom from aneurysm-related mortality was 58 ± 6% at 5 years and 53 ± 6% at 7 years. In patients surviving the perioperative 30-day interval, freedom from aneurysm-related mortality was 73 ± 6% at 5 years and 66 ± 7% at 7 years. Primary target vessel patency at 5 and 7 years was 87 ± 4%, with renal arteries most frequently affected. Late reinterventions occurred in 16.1% of patients, mostly for type Ia endoleaks (8 of 25 reinterventions (32%)) and type Ib endoleaks (5 of 25 reinterventions (20%)). CONCLUSION: In this Parallel Endografting And Chimney Endovascular (PEACE) registry study, chEVAR was associated with a high rate of technical success and acceptable early outcomes, but, in the longer term, was associated with high rates of reintervention and mortality. It appears to represent a reasonable alternative technique for patients presenting as an emergency with complex aortic aneurysm morphology when standard open and endovascular techniques are not feasible.
引用
- Karelis A, Adam D, Piazza M, et al. Parallel Endografting And Chimney Endovascular (PEACE) registry outcomes in emergency repair of complex abdominal aortic aneurysms. Br J Surg. 2025. PMID: 41467577. doi:10.1093/bjs/znaf278
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。